OBJECTIVE： To systematically review the safety of empagliflozin in the treatment of type 2 diabetes， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from Cochrane Library， PubMed， EMBase， CNKI， Wanfang Database and VIP， randomized controlled trials （RCT） about empagliflozin （test group） versus other drugs （control group） in the treatment of type 2 diabetes were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation. RESULTS： Totally 7 RCTs were included， involving 10 267 patients. Results of Meta-analysis showed the incidence of adverse reactions in test group was significantly lower than control group [RR＝0.98，95％CI（0.97，0.99），P＝0.006]， the incidence of reproductive tract infection-related events was significantly higher than control group[RR＝3.85，95％CI（3.11， 4.75），P＜0.001]； there was no significant difference in the incidences of hypoglycemic events [RR＝1.01，95％CI（0.96，1.07）， P＝0.66] and urinary tract infection events [RR＝1.00，95％CI（0.91，1.10），P＝0.95]. CONCLUSIONS： Empaglifozin has good overall safety in the treatment of type 2 diabetes， clinical application should notice preventing reproductive tract infection.